Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

TNF-Bound Colloidal Gold in Treating Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00356980
Recruitment Status : Completed
First Posted : July 27, 2006
Last Update Posted : March 15, 2012
National Cancer Institute (NCI)
Information provided by:
National Institutes of Health Clinical Center (CC)

Brief Summary:

RATIONALE: Biological therapies, such as TNF-bound colloidal gold, may stimulate the immune system in different ways and stop tumor cells from growing.

PURPOSE: This phase I trial is studying the side effects and best dose of TNF-bound colloidal gold in treating patients with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Unspecified Adult Solid Tumor, Protocol Specific Biological: colloidal gold-bound tumor necrosis factor Other: pharmacological study Phase 1

Detailed Description:



  • Determine the maximum tolerated dose of TNF-bound colloidal gold (CYT-6091) in patients with advanced solid tumors.
  • Determine the toxicities of CYT-6091 in these patients.


  • Determine the pharmacokinetics of CYT-6091 in these patients.
  • Evaluate biopsy samples of tumor and adjoining normal tissue for levels of CYT-6091.
  • Determine if antitumor effects of CYT-6091 occur in these patients.

OUTLINE: This is an open-label, sequential cohort, dose-escalation study.

Patients receive TNF-bound colloidal gold (CYT-6091) IV on days 1 and 15 (course 1). Approximately 4-6 weeks later, patients are re-staged and responding patients may receive another course of therapy. Patients may receive up to 3 re-treatment courses.

Cohorts of 3-6 patients receive escalating doses of CYT-6091 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 1 of 6 patients experience dose-limiting toxicity.

Blood samples are collected at baseline and periodically during the first course of therapy for pharmacokinetic and pharmacodynamic analyses.

After completion of study treatment, patients are followed every 3 months for 1 year, every 4 months for the next year, and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Trial of TNF-Bound Colloidal Gold (CYT-6091) by Intravenous Administration in Subjects With Advanced Solid Organ Malignancies
Study Start Date : May 2006
Actual Primary Completion Date : February 2009
Actual Study Completion Date : April 2009

Primary Outcome Measures :
  1. Maximum tolerated dose of TNF-bound colloidal gold (CYT-6091)
  2. Toxicity

Secondary Outcome Measures :
  1. Pharmacokinetic profile of CYT-6091
  2. Measurements of CYT-6091 in tumor biopsies
  3. Tumor biopsy histology and gene expression after treatment
  4. Immunogenicity of CYT-6091
  5. Electron microscopy of biopsy to determine presence of colloidal gold
  6. Response of target and nontarget lesions
  7. Overall response
  8. Duration of response
  9. Duration of stable disease

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed solid tumor
  • Advanced and/or metastatic disease
  • Unresponsive to conventional therapy (i.e., disease progressed while receiving any known standard curative or palliative therapy) OR previously untreated tumor for which no standard treatment exists
  • Measurable or evaluable metastatic disease
  • No lymphoma or other hematologic malignancy
  • No known brain metastases

    • Previously treated brain metastases with no evidence of recurrence allowed


  • ECOG performance status 0-2
  • Life expectancy ≥ 3 months
  • Absolute neutrophil count ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Creatinine ≤ 2.0 mg/dL
  • Bilirubin ≤ 2.5 mg/dL
  • ALT and AST ≤ 1.5 times upper limit of normal (ULN) (3 times ULN if liver metastases are present)
  • Alkaline phosphatase ≤ 1.5 times ULN (3 times ULN if liver metastases are present)
  • Prothrombin time ≤ 1.5 times ULN
  • Hemoglobin ≥ 10.0 g/dL (transfusion allowed)
  • LVEF ≥ 45% by echocardiogram or thallium stress test for patients > 50 years of age or history of cardiovascular disease
  • FEV_1 and DLCO > 30% of predicted for patients with a history of pulmonary disease
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No active bacterial or viral infection with systemic manifestations (e.g., fever, symptoms, leukocytosis)

    • Localized chronic infections, such as mild acne or tinea pedis allowed
  • No acute or chronic viral hepatitis
  • No known bleeding disorder
  • No other concurrent life-threatening illness, including any of the following:

    • Unstable angina
    • Severe oxygen-dependent chronic obstructive pulmonary disease
    • End-stage liver disease
  • No known active renal disease or renal insufficiency as evidenced by serum creatinine > 2.0 mg/dL
  • No HIV positivity


  • Recovered from prior therapy
  • More than 3 weeks since prior biological or cytotoxic agents (6 weeks for nitrosoureas)
  • No known requirment for palliative treatment
  • No concurrent surgery
  • No other concurrent anticancer therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00356980

Layout table for location information
United States, Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
Bethesda, Maryland, United States, 20892-1182
NCI - Surgery Branch
Bethesda, Maryland, United States, 20892-1201
Sponsors and Collaborators
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Steven K. Libutti, MD NCI - Surgery Branch
Publications of Results:
Layout table for additonal information Identifier: NCT00356980    
Obsolete Identifiers: NCT00328406
Other Study ID Numbers: 060167
First Posted: July 27, 2006    Key Record Dates
Last Update Posted: March 15, 2012
Last Verified: March 2012
Keywords provided by National Institutes of Health Clinical Center (CC):
unspecified adult solid tumor, protocol specific